TelevisaUnivision Announces Fourth Quarter and Full Year 2025 Results
TelevisaUnivision reduced its 2025 losses to $235 million with ViX streaming profits offsetting a 11% drop in U.S. advertising revenue, CEO Alegre said.
- On Feb. 23, 2026 BioMarin announced full-year 2025 results and provided 2026 guidance, with revenues expected to be $3,325 to $3,425 million.
- VOXZOGO's sales surged, driving 17% total revenue growth in 2025, while Enzyme Therapies advanced 9%, supported by PALYNZIQ, and BioMarin expanded VOXZOGO CANOPY with five new indications.
- Full-Year GAAP results show a net loss of $ million, while non-GAAP results reported $47.7 million net income and a 16.5% gross margin for 2025.
- The acquisition of Amicus Therapeutics, expected to close in Q2'26, includes $3.7 billion in financing, and management expects a Non‑GAAP Operating Margin of approximately 40% for 2026, excluding the post-close impact.
- Upcoming regulatory dates include a PALYNZIQ U.S. PDUFA date on February 28, 2026, and other 1H'26 program milestones; the press release contains extensive forward‑looking statements subject to risks, BioMarin said.
40 Articles
40 Articles
Option Care Health Announces Financial Results for Fourth Quarter and Full Year 2025
BANNOCKBURN, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter…
TelevisaUnivision Narrows Losses in Q4
Spanish-language media giant TelevisaUnivsion said it narrowed its losses in the fourth quarter as it generated profits from its ViX streaming service and grappled with sluggish ad trends in the United States. The owner of the Univision TV network reported a net loss of $234.7 million, compared with a loss of $809.7 million in the […]
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium



















